[1]邱隆霞.沙库巴曲缬沙坦对射血分数保留心功能衰竭患者临床症状及心功能的影响[J].医学信息,2025,38(09):92-96.[doi:10.3969/j.issn.1006-1959.2025.09.017]
　QIU Longxia.Effect of Sacubitril/Valsartan on Clinical Symptoms and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction[J].Journal of Medical Information,2025,38(09):92-96.[doi:10.3969/j.issn.1006-1959.2025.09.017]
点击复制

沙库巴曲缬沙坦对射血分数保留心功能衰竭患者临床症状及心功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年09期
页码:
92-96
栏目:
论著
出版日期:
2025-05-01

文章信息/Info

Title:
Effect of Sacubitril/Valsartan on Clinical Symptoms and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
文章编号:
1006-1959（2025）09-0092-05
作者:
邱隆霞
上饶市广丰区人民医院药剂科，江西 上饶 334600
Author(s):
QIU Longxia
Department of Pharmacy, Shangrao Guangfeng District People’s Hospital, Shangrao 334600, Jiangxi, China
关键词:
沙库巴曲缬沙坦; 射血分数保留心功能衰竭; 心功能
Keywords:
Sacubactril/valsartan;  Heart failure with preserved ejection fraction;  Cardiac function
分类号:
R541.61
DOI:
10.3969/j.issn.1006-1959.2025.09.017
文献标志码:
A
摘要:
目的 探究沙库巴曲缬沙坦对射血分数保留心功能衰竭患者临床症状及心功能的影响。方法 选取2021年1月-2023年6月上饶市广丰区人民医院收治的射血分数保留心功能衰竭患者62例为研究对象，根据随机数字表法分为对照组与研究组，各31例。对照组采取常规治疗，研究组采取沙库巴曲缬沙坦口服治疗。比较两组临床疗效、心功能[左心室舒张末期内径（LVDd）、左心室收缩末期内径（LVDs）、室间隔舒张末期厚度（IVSd）、左心室后壁舒张末期厚度（LVPWd）]、心血管不良事件（心血管死亡、恶性心律失常、心力衰竭加重）发生率、炎性因子水平[超敏C反应蛋白（hs-CRP）、白细胞介素（IL）-6、肿瘤坏死因子（TNF）-α]、临床症状（呼吸困难、体力活动受限、胸闷、气短）评分。结果 与对照组治疗总有效率的74.19%比较，研究组治疗总有效率更高，达96.77%（P＜0.05）；与对照组心血管不良事件发生率的16.13%比较，研究组心血管不良事件发生率更低，为0（P＜0.05）；与治疗前比较，两组治疗后心功能指标（LVDd、LVDs、IVSd、LVPWd）、炎性因子水平（hs-CRP、IL-6、TNF-α）、临床症状评分（呼吸困难、体力活动受限、胸闷、气短）降低，且与对照组比较，研究组治疗后心功能指标（LVDd、LVDs、IVSd、LVPWd）、心功能指标（LVDd、LVDs、IVSd、LVPWd）、炎性因子水平（hs-CRP、IL-6、TNF-α）、临床症状评分（呼吸困难、体力活动受限、胸闷、气短）更低（P＜0.05）。结论 沙库巴曲缬沙坦在射血分数保留心功能衰竭患者治疗中的临床疗效确切，能够改善患者心功能及临床症状，减轻患者炎性反应，降低患者心血管不良事件发生率。
Abstract:
Objective To investigate the effect of sacubitril/valsartan on clinical symptoms and cardiac function in patients with heart failure with preserved ejection fraction. Methods A total of 62 patients with heart failure with preserved ejection fraction admitted to Shangrao Guangfeng District People’s Hospital from January 2021 to June 2023 were selected as the research objects. According to the random number table method, they were divided into control group and study group, with 31 patients in each group. The control group was treated with routine treatment, and the study group was treated with sacubitril/valsartan orally. The clinical efficacy, cardiac function [left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVDs), interventricular septal thickness in diastole (IVSd), left ventricular posterior wall end-diastolic thickness (LVPWd)], incidence of cardiovascular adverse events (cardiovascular death, malignant arrhythmia, aggravation of heart failure), levels of inflammatory factors [high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-α], clinical symptoms (dyspnea, physical activity limitation, chest tightness, shortness of breath) scores were compared between the two groups. Results Compared with 74.19% of the total effective rate of the control group, the total effective rate of the study group was higher, reaching 96.77% (P<0.05). Compared with 16.13% of the incidence of cardiovascular adverse events in the control group, the incidence of cardiovascular adverse events in the study group was lower, which was 0 (P<0.05). Compared with before treatment, the cardiac function indexes (LVDd, LVDs, IVSd, LVPWd), inflammatory factor levels (hs-CRP, IL-6, TNF-α) and clinical symptom scores (dyspnea, physical activity limitation, chest tightness, shortness of breath) decreased in the two groups after treatment, and compared with the control group, the cardiac function indexes (LVDd, LVDs, IVSd, LVPWd), cardiac function indexes (LVDd, LVDs, IVSd, LVPWd), inflammatory factor levels (hs-CRP, IL-6, TNF-α), clinical symptom scores (dyspnea, limited physical activity, chest tightness, shortness of breath) were lower in the study group after treatment (P<0.05). Conclusion Sacubitril/valsartan has a definite clinical effect in the treatment of patients with heart failure with preserved ejection fraction, which can improve their heart function and clinical symptoms, reduce the inflammatory response and reduce the incidence of cardiovascular adverse events.

参考文献/References:

[1]Omote K,Verbrugge FH,Borlaug BA.Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies[J].Annu Rev Med,2022,73:321-337.[2]Fauchier L,Bisson A,Bodin A.Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions[J].BMC Med,2023,21(1):54.[3]Vaduganathan M,Mentz RJ,Claggett BL,et al.Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF[J].Eur Heart J,2023,44(31):2982-2993.[4]杜彦梅,衣欣.沙库巴曲缬沙坦治疗射血分数保留心功能衰竭的效果分析[J].中国医药科学,2022,12(8):142-146.[5]李金莲,杨帆,宁新惠.沙库巴曲缬沙坦对老年射血分数保留型心力衰竭患者无创心功能和脉搏波传导速度的影响[J].中国老年学杂志,2023,43(10):2309-2312.[6]李水英,谢达奇.沙库巴曲缬沙坦对左心室射血分数保留心力衰竭老年患者左室重构及心功能的影响[J].全科医学临床与教育,2022,20(3):239-242.[7]崔文光.沙库巴曲缬沙坦联合有氧运动对射血分数保留心力衰竭患者心肺功能的影响[D].张家口:河北北方学院,2023.[8]张小丹,张巧玲,朱志勇,等.沙库巴曲缬沙坦钠联合常规对症治疗射血分数保留心力衰竭患者的临床疗效及安全性研究[J].海南医学,2024,35(2):174-178.[9]Pieske B,Wachter R,Shah SJ,et al.Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial[J].JAMA,2021,326(19):1919-1929.[10]郑玉雯,张磊,严喜胜,等.沙库巴曲缬沙坦钠治疗射血分数保留的心力衰竭患者临床观察[J].中国药业,2024,33(1):101-104.[11]Jackson AM,Jhund PS,Anand IS,et al.Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J].Eur Heart J,2021,42(36):3741-3752.[12]崔玉兰,索云锡,王森,等.苓桂术甘汤联合沙库巴曲缬沙坦钠片治疗左室射血分数保留心力衰竭的研究[J].现代中西医结合杂志,2023,32(6):823-827.[13]Ledwidge M,Dodd JD,Ryan F,et al.Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial[J].JAMA Cardiol,2023,8(4):366-375.[14]陈利,赵一奇,葛宏想,等.沙库巴曲缬沙坦治疗急性心肌梗死合并射血分数保留型心力衰竭的疗效及预后分析[J].心肺血管病杂志,2023,42(5):400-405.[15]杨小刚,赵月琛,王文彬,等.沙库巴曲缬沙坦治疗射血分数保留型心力衰竭的临床疗效及预后的影响[J].现代医学与健康研究(电子版),2023,7(15):39-42.[16]严聪玲,杨吉操,胡东旭.沙库巴曲缬沙坦辅助托伐普坦治疗老年高血压伴射血分数保留心衰的疗效[J].医学理论与实践,2023,36(15):2558-2560.[17]赵新宇,张力之,刘莉.沙库巴曲缬沙坦治疗维持性血液透析合并射血分数保留型心衰患者的临床疗效分析[J].医学研究杂志,2023,52(11):154-158,169.[18]张国华,汝晓雪,王鑫伟,等.沙库巴曲缬沙坦口服治疗射血分数保留的心力衰竭临床效果观察[J].山东医药,2022,62(23):52-54.[19]吴聪聪.沙库巴曲缬沙坦钠联合螺内酯、美托洛尔治疗左室射血分数保留心衰患者的疗效观察[J].检验医学与临床,2022,19(4):548-550.[20]马潇泓,王鸣,张维.沙库巴曲缬沙坦钠治疗老年射血分数保留的心力衰竭合并肾功能不全患者的疗效观察[J].老年医学与保健,2022,28(5):1105-1109.[21]曹祯,丁爱梅,王向明,等.沙库巴曲缬沙坦治疗射血分数保留心功能衰竭的效果研究[J].中国循证心血管医学杂志,2022,14(8):967-970.[22]刘金明,黄彩虹,肖根发,等.沙库巴曲缬沙坦钠片对射血分数保留心力衰竭患者心功能及氧化应激指标的影响[J].中国医学创新,2022,19(19):27-31.[23]赵晓宁,刘志远,刘江波,等.左西孟旦联合沙库巴曲缬沙坦钠对射血分数保留型心力衰竭患者心功能、心室重塑及预后的影响[J].中国合理用药探索,2022,19(12):51-56.

相似文献/References:

[1]李 龙,汪莲开.沙库巴曲缬沙坦在心力衰竭治疗中的应用[J].医学信息,2020,33(02):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
　LI Long,WANG Lian-kai.Application of Shakubatrivasartan in the Treatment of Heart Failure[J].Journal of Medical Information,2020,33(09):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
[2]韦怡春,易秋艳.沙库巴曲缬沙坦对心力衰竭患者抑郁的影响[J].医学信息,2021,34(23):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
　WEI Yi-chun,YI Qiu-yan.Effect of Sacubitril Valsartan on Depression in Patients with Heart Failure[J].Journal of Medical Information,2021,34(09):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
[3]熊鹏锋.沙库巴曲缬沙坦联合美托洛尔对青年扩张型心肌病患者心功能及预后的影响[J].医学信息,2022,35(20):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
　XIONG Peng-feng.Effect of Sacubitril Valsartan Combined with Metoprolol on Cardiac Function and Prognosis in Young Patients with Dilated Cardiomyopathy[J].Journal of Medical Information,2022,35(09):80.[doi:10.3969/j.issn.1006-1959.2022.20.020]
[4]袁 超.沙库巴曲缬沙坦联合比索洛尔治疗慢性心力衰竭的效果[J].医学信息,2020,33(19):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
　YUAN Chao.Effect of Sacubitril Valsartan Combined with Bisoprolol in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2020,33(09):135.[doi:10.3969/j.issn.1006-1959.2020.19.041]
[5]王晨青,李婧炜.沙库巴曲缬沙坦在心力衰竭中的应用现状[J].医学信息,2021,34(01):37.[doi:10.3969/j.issn.1006-1959.2021.01.011]
　WANG Chen-qing,LI Jing-wei.The Application Status of Sacubatril Valsartan in Heart Failure[J].Journal of Medical Information,2021,34(09):37.[doi:10.3969/j.issn.1006-1959.2021.01.011]
[6]龚殿炳.芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的临床效果及对心室重构的影响[J].医学信息,2023,36(23):99.[doi:10.3969/j.issn.1006-1959.2023.23.025]
　GONG Dian-bing.Clinical Effect of Qili Qiangxin Capsules Combined with Sacubitril Valsartan in Treatment of Chronic Heart Failure and its Effect on Ventricular Remodeling[J].Journal of Medical Information,2023,36(09):99.[doi:10.3969/j.issn.1006-1959.2023.23.025]
[7]葛文涛,程长生,胡成坤.强心贴联合沙库巴曲缬沙坦对慢性心力衰竭患者脑钠肽水平的影响[J].医学信息,2025,38(04):132.[doi:10.3969/j.issn.1006-1959.2025.04.024]
　GE Wentao,CHENG Changsheng,HU Chengkun.Effect of Qiangxin Paste Combined with Sacubitril Valsartan on Brain Natriuretic Peptide Level in Patients with Chronic Heart Failure[J].Journal of Medical Information,2025,38(09):132.[doi:10.3969/j.issn.1006-1959.2025.04.024]
[8]刘文烜,胡 晋,钟小丽,等.沙库巴曲缬沙坦联合八段锦对心力衰竭合并室性心律失常的临床疗效研究[J].医学信息,2025,38(09):105.[doi:10.3969/j.issn.1006-1959.2025.09.020]
　LIU Wenxuan,HU Jin,ZHONG Xiaoli,et al.Study on the Clinical Effect of Sacubitril/Valsartan Combined with Baduanjin on Heart Failure Complicated with Ventricular Arrhythmia[J].Journal of Medical Information,2025,38(09):105.[doi:10.3969/j.issn.1006-1959.2025.09.020]

更新日期/Last Update: 1900-01-01